Is CRON stock a Buy, Sell, or Hold?

Based on our analysis, CRON is currently a HOLD with moderate confidence. 📊 HOLD: CRON shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of CRON stock?

Our analysis estimates the fair value range for CRON to be between $2.59 and $2.73. The current price is $2.51.

What is the analyst price target for CRON?

The average Wall Street analyst price target for CRON is $2.36. This implies a potential upside of -8.9% from current levels.

CRON Stock Analysis: Buy, Sell, or Hold?

CRON - Cronos Group Inc. Common Share

MEDICINAL CHEMICALS & BOTANICAL PRODUCTS

$2.51

-0.08 (-3.09%) ▼

HOLD

MODERATE Confidence

Protect Your CRON Gains

Last Updated: January 30, 2026

Earnings: Feb 26, 2026 25d

Get Alerted When CRON Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: CRON shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

In-depth Analysis How we analyze

Valuation Analysis: CRON is currently trading at $2.51, which is considered oversold relative to its 30-day fair value range of $2.59 to $2.73. The stock's valuation (Forward PE: 22.4) is in line with its historical norms (23.4). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This pessimistic expectation contrasts with the company's recent 238.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, CRON is in a strong uptrend. The price is currently testing key support at $2.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.

Market Sentiment: CRON has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD

Fair Price Range $2.59 - $2.73

Company Quality Score 54/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 45.2%

Protect Your Profits

Holding CRON? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
BEARISH: Weak technical setup (25/100)
BULLISH: High volume confirmation
BEARISH: Downward momentum (-3.1%)
BEARISH: Trading above Wall St target ($2.36)
CAUTION: 5-day price weakness (-9.7%) - monitor closely

Fair Price Analysis

30-Day Fair Range $2.59 - $2.73

Current vs Fair Value OVERSOLD

Support & Resistance Levels

Support Level $2.50

Resistance Level $2.83

Current Trend Strong Uptrend

Fundamental Context

Forward P/E (Next Year Est.) 22.39

Wall Street Target $2.36 (-8.9%)

Revenue Growth (YoY) 6.1%

Earnings Growth (YoY) 238.8%

Profit Margin 27.3%

Valuation Discount vs History -1.5% cheaper

PE vs Historical 22.4 vs 23.4 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -1.5% (market-implied from PE analysis)

1-Year Target $2.55 (-2%)

2-Year Target $2.51 (-3%)

3-Year Target $2.48 (-4%)

3-Yr Target (if PE normalizes) (PE: 22→23) $2.59 (0%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (22x PE) as earnings recover.

Trailing PE: 24.18 | Current EPS (TTM): $0.11

Bull Case $3.08 (+23%)

Analyst growth 5.2%, PE expands to 26.6

Base Case $2.80 (+12%)

Market implied 5.2%, PE stable at 24.2

Bear Case $1.81 (-28%)

Severe decline -20.0%, PE contracts to 20.6

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 22.4 to 23.4

Stabilization Target: $2.71 (+4.5%)

PE Expansion Potential: +4.5%

Last updated: January 31, 2026 2:32 AM ET
Data refreshes hourly during market hours. Next update: 3:32 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is CRON showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
NBIX Neurocrine Biosciences I…	STRONG BUY 25 analysts	$179	62 BUY
ZTS Zoetis Inc	STRONG BUY 19 analysts	$158	56 HOLD
LNTH Lantheus Holdings Inc	STRONG BUY 13 analysts	$84	57 HOLD
BCRX BioCryst Pharmaceuticals…	STRONG BUY 12 analysts	$21	55 HOLD
HCM HUTCHMED DRC	STRONG BUY 14 analysts	$21	57 HOLD

NBIX Neurocrine Biosci…

62 BUY

ZTS Zoetis Inc

56 HOLD

LNTH Lantheus Holdings…

57 HOLD

BCRX BioCryst Pharmace…

55 HOLD

HCM HUTCHMED DRC

57 HOLD

Advanced CRON Option Strategies

Professional options setups generated by AI based on today's CRON price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for CRON

CRON Technical Chart CRON Price Prediction CRON Earnings Date CRON Investment Advisor CRON Fair Price Analyzer CRON Options Advisor CRON Options Chain CRON Options Analysis CRON Competitors

Compare CRON with Other Stocks

Create New Comparison

Tradestie